Introduction {#s1}
============

The mitral valve apparatus is a complex structure consisting of the mitral leaflets, chordae tendineae, papillary muscles, and mitral annulus. Abnormalities of any of these structures may cause mitral regurgitation (MR) \[[@R01]\]. Causes could be inflammatory such as rheumatic heart disease and connective tissue disorders; degenerative such as myxomatous degeneration of mitral valve leaflets or annulus; infective such as infective endocarditis; structural such as ruptured chordae tendineae, papillary muscle dysfunction (ischemia or myocardial infarction) and annular dilation; and congenital such as mitral valve clefts or fenestrations, parachute mitral valve, to name a few.

Because the regurgitant mitral orifice is functionally in parallel with the aortic valve, the impedance to ventricular emptying is reduced in patients with MR. Consequently, MR enhances left ventricular (LV) emptying. Almost 50% of the regurgitant volume (RV) is ejected into the left atrium (LA) before the aortic valve opens. The RV depends on a combination of the instantaneous size of the regurgitant orifice and the (reverse) pressure gradient between the LV and LA \[[@R02]\]. In chronic MR, left ventricular end-diastolic volume (LVEDV) increases and left ventricular end-systolic volume (LVESV) returns to normal. By means of the Laplace principle, the increased LVEDV increases wall tension to normal or supernormal levels in the so-called chronic compensated stage \[[@R03]\]. The resultant increase in LVEDV and mitral annular diameter may create a vicious circle, in which MR begets to more MR. In patients with chronic MR, eccentric hypertrophy develops but reduces after load permits maintenance of ejection fraction (EF) in the normal to supernormal range. In most patients with severe MR, compensation is maintained for years, but in some prolonged hemodynamic overload ultimately leads to myocardial decompensation \[[@R04]\]. LVESV, preload and after load all increase, whereas EF and stroke volume decline.

Patients develop symptoms because of elevated LA and pulmonary venous pressures related to the RV despite no apparent change in ejection phase indices such as EF, fractional fiber shortening, and velocity of circumferential fiber shortening (VCF) as these are after load dependent which is reduced initially \[[@R04]\]. However, in other patients, major symptoms reflect serious contractile dysfunction, at which time these indices have declined to low-normal or below-normal levels. Therefore, values in the low-normal range for the ejection phase indices in patients with chronic MR may actually reflect impaired myocardial function, whereas moderately reduced values (EF: 40-50%) signify severe, often irreversible, impairment of contractility, identifying patients who may do poorly after surgical correction of the MR. Subjects with EF \< 60% and/or end-systolic diameter (ESD) ≥ 40 mm should be considered as patients with manifest LV dysfunction even if they are asymptomatic and, where it is not contraindicated, they should receive salvage surgery \[[@R05]\]. This implies a discrepancy with current recommendations, but using EF \< 60% and ESD ≥ 40 mm as indicators for surgery may involve too long a delay and will lead to poorer medium- and long-term survival.

The optimal timing of surgery in patients with asymptomatic severe MR continues to be debated. Current guidelines recommend for intervention in presence of symptoms, pulmonary hypertension (PAH), new onset atrial fibrillation (AF) or incipient LV dysfunction. LVESD, LA size and EF have been found to allow risk stratification in asymptomatic patients among several echocardiographic parameters. Effective regurgitant orifice (ERO) area, a marker of hemodynamic consequences, has also been shown to correlate with adverse outcomes. Echocardiography, however, is operator dependent and has several limitations. Therefore, there is a growing need for other objective measures to help identify patients with severe MR with subtle LV dysfunction.

Risk stratification of asymptomatic patients {#s1a}
--------------------------------------------

Because the outcomes of MV surgery are not optimal in all cases, all authoritative guidelines include clinically accessible measures of LV remodeling and "function" to identify asymptomatic patients at higher risk and should help ascertain the ideal timing of intervention to preserve LV function and not simply avert a poor outcome. Symptoms are often unreliable as they are subjective but provide reassurance that intervention can be safely delayed in asymptomatic patients. It can be also done by rest and stress echocardiography, tissue Doppler and myocardial deformation imaging and natriuretic peptides.

Apart from LV dimensions, volumes and function, direct quantization of MR is performed by the proximal isovelocity surface area (PISA) technique. While exponents of the PISA method vouch for its accuracy and reproducibility \[[@R06]\], it has only modest reliability and significant interobserver variability. Other limitations of PISA technique include geometric assumptions of the flow convergence zone \[[@R07]\]. Given these pitfalls, assessment of MR severity should integrate quantitative and qualitative data, including vena contracta width, and pulmonary vein systolic flow reversal. Stress echocardiography can evaluate contractile reserve (CR) and also unmask PAH in asymptomatic patients. Exercise-induced PAH (pulmonary artery systolic pressure (PASP) \> 60 mm Hg) is associated with markedly lower 2-year symptom-free survival, and appears superior to resting PAH for predicting the occurrence of symptoms \[[@R08]\].

In chronic organic MR, incipient LV dysfunction may also be detected by tissue Doppler imaging (TDI) based on assessment of LV long axis function which appears to be deranged earlier than radial shortening. Haluska et al \[[@R09]\] showed that peak annular systolic velocity (S~m~) was the only resting echocardiographic parameter that could discriminate patients with and without cardiac rehabilitation (CR). The differences in peak S~m~ were even greater after stress. In one study, S~m~ ≤ 10 cm/s was independently associated with a \> 10% postoperative reduction in LVEF \[[@R10]\].

Compared to TDI, myocardial strain imaging is less influenced by cardiac translation and tethering \[[@R11], [@R12]\]. "Pseudonormalization" of myocardial strain in chronic MR, whereby fiber shortening is enhanced in the compensated state but later decreases with disease progression, suggests that normalization for preload or LV geometry is required to appropriately interpret this parameter \[[@R13]\]. Therefore, reports are conflicting on the value of preoperative speckle-tracking strain imaging in predicting postoperative LV dysfunction \[[@R14], [@R15]\].

Brain natriuretic peptide (BNP) {#s1b}
-------------------------------

Human cardiocytes manufacture a family of structurally related peptides whose release is stimulated by hemodynamic stress as wall stretch, ventricular dilatation and/or increased pressure resulting from fluid overload, ventricular hypertrophy, systemic hypertension, hypervolemia, PAH, increasing age, increased LA size and hyperthyroidism, to name a few ([Table 1](#T1){ref-type="table"}). It consists of five structurally similar peptides, i.e. atrial natriuretic peptide (ANP), urodilatin (an isoform of ANP), BNP, C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide (DNP) \[[@R16]\]. Of them, BNP and its related cleavage products have emerged as superior markers for congestive heart failure (CHF) and LV dysfunction because of its rapid upregulation at the transcriptional level, more stable than other peptides and more sensitive to ventricular dysfunction.

###### Natriuretic Peptides and Its Types

  Natriuretic peptide   Amino acid length   T~1/2~ (min)   Source              Stimulus for release
  --------------------- ------------------- -------------- ------------------- ----------------------------------------------------------
  ANP                   28                  3              Atria               ↑ atrial pressure, stretching
  NANP                  98                  54             Atria               ↑ atrial pressure, stretching
  NT-ProBNP             76                  60 - 120       Ventricles          ↑ ventricular volume, stretching, end-diastolic pressure
  BNP                   32                  22             Ventricles          ↑ ventricular volume, stretching, end-diastolic pressure
  CNP (two isoforms)    53, 22              42406          Peripheral vessel   Unclear

ANP: atrial natriuretic peptide; NANP: N-terminal atrial natriuretic peptide; NT-ProBNP: N-terminal pro­B-type natriuretic peptide; BNP: B-type natriuretic peptide; CNP: C-type natriuretic peptide; T~1/2~: half life.

Natriuretic peptides have much potential in the risk stratification of asymptomatic patients with hemodynamically significant valvular lesions well as in their routine surveillance and monitoring. In patients with primary MR, it is known to be a good surrogate marker of its consequences on the LV, LA and PASP \[[@R17]\] and is a powerful predictor of outcome. In the management of asymptomatic patients with MR, current ACC/AHA and ESC guidelines for valvular heart disease recommend performing exercise testing in order to obtain objective assessment of symptomatic status and to assess the exercise tolerance. In addition, MR severity \[[@R20]\] and PASP \[[@R21]\] quantified at peak exercise are superior to these parameters evaluated at rest for predicting the occurrence of symptoms. Therefore, the measurement of BNP at exercise could provide an incremental value as compared with standard resting BNP for the risk stratification of patients with asymptomatic MR.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

The aim of this study was to determine the independent and additive prognostic value of exercise brain natriuretic peptide (eBNP) over resting brain natriuretic peptide in patients with chronic organic severe asymptomatic MR and normal LV function. It was a prospective, single-center trial conducted in the Department of Cardiology, LPS Institute of Cardiology, G.S.V.M. Medical College, Kanpur, UP, India between October 2013 and March 2015. Three hundred twenty-five consecutive patients were enrolled with chronic severe organic asymptomatic MR as defined by ERO area ≥ 40 mm^2^, and/or RV ≥ 60 mL, preserved LVEF \> 60% and LVESD \< 40 mm. Exclusion criteria were patients with LVESD \> 40 mm, LVEF \< 60%, permanent AF, with associated valve disease (aortic valve disease, moderate or severe mitral stenosis, or significant right organic valve disease), renal dysfunction (SCr \> 2.5 mg/dL), ischemic MR, previous valve surgery, dilated cardiomyopathy (DCM), inadequate transthoracic echocardiogram (TTE) imaging window, and terminal disease with expected survival ≤ 1 year. Informed consent was obtained from each patient enrolled in the study. Patients were followed up every 3 months up to 15 months. Endpoint cardiac events were defined as the occurrence of cardiovascular (CV) death, need for mitral valve surgery based on current guideline recommendation by ESC/ACC/AHA, and hospitalization for acute pulmonary edema or CHF.

Data collection {#s2b}
---------------

Enrolled patients underwent complete evaluation including detailed clinical examination and investigations including ECG and then were subjected to cardiac echocardiography and symptom limited exercise treadmill test (TMT). Coronary angiography was performed using the Judkins' method by radial route using Tiger catheter (Terumo Inc., Japan) as a part of their diagnostic protocol to rule out ischemic MR or DCM. Venous blood samples were withdrawn for quantification of BNP before echo (i.e., after 30 min of supine rest), and at exercise (i.e., within the 3 min of the end of effort) for eBNP using Alere triage BNP kits by Alere Triage MeterPro 55070 machine.

Dyspnea was graded according to the NYHA classification. All subjects underwent a symptom limited exercise TMT by standard Bruce protocol. Blood pressure was recorded at the end of each stage. Exercise was stopped in lieu of marked dyspnea, fatigue, chest discomfort, ≥ 2 mm ST depression, and significant arrhythmia or slowing of heart rate and on patient request.

Echo and exercise test protocol {#s2c}
-------------------------------

Echocardiography was performed with Vivid7 (GE) instrument. LVEDD and LVESD by M-mode in standard parasternal long-axis (PLAX) view using the leading edge methodology at end-diastole and end-systole, LVEDV/LVESV/LVEF by modified biplane Simpson's method, LA volume by area-length method, mitral E- and A-wave velocities by pulsed-wave Doppler, Ea-wave velocity by tissue Doppler imaging in the septal position of the mitral annulus, MR quantification by quantitative Doppler with mitral and aortic stroke volumes, and PISA which was further averaged allowing calculation of RV, regurgitation fraction (RF), and ERO area, PASP by regurgitant jet of tricuspid regurgitation (TR), comprehensive LV myocardial function by the global longitudinal strain (GLS) using 2D speckle tracking were analyzed. Furthermore, exercise echocardiographic images were obtained in the apical four-chamber view for LV volumes followed by TR jet velocity for PASP within 1 min of peak exercise.

Statistical analysis {#s2d}
--------------------

Continuous variables were expressed as mean ± SD, while discrete variables were presented as frequency and percentage. Patients were stratified in three tertiles according to eBNP level (*post hoc* analysis). Differences between groups were analyzed for statistical significance with one-way analysis of variance (ANOVA), χ^2^ test, or Fisher's exact test as appropriate. The statistical difference between resting and eBNP was obtained using paired *t*-test. Correlations between echocardiographic data and BNP level were assessed with linear regressions method. Sensitivity and specificity for prediction of the occurrence of events were determined for various cut-off values of eBNP level using receiver operating characteristic (ROC) curves. The impact of BNP level on outcome was assessed according to tertiles. Values of P \< 0.05 were considered statistically significant. All statistical analyses were performed with STATISTICA version 7 (StatSoft Inc., Tulsa, OK, USA).

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

Baseline characteristics of patients are described in [Table 2](#T2){ref-type="table"}. Mean age was 31.2 ± 9 years (range: 18 - 40) with majority being male (n = 153; 68%). The etiologies of chronic MR were rheumatic (n = 201; 90%), mitral valve prolapse (n = 17; 7.6%) and hypertrophic cardiomyopathy (n = 5; 2.4%). BNP level at rest was 65.24 ± 43.92 pg/mL (median: 43.5) with statistically significant rise to exercise level (100.24 ± 98.24 pg/mL; median: 66.5; P \< 0.001). Patients were then divided into three tertiles based on eBNP level (T~1~ = 15 - 44 pg/mL; T~2~ = 45 - 104 pg/mL; T~3~ = 105 - 400 pg/mL). There were 76 (34%), 77 (34%) and 70 (31%) in T~1~, T~2~ and T~3~, respectively.

###### Baseline Characteristics of Patients (N = 223)

  Variables                        No. (%)
  -------------------------------- -------------------------------
  Age (years)                      31.2 ± 9
  Sex (M:F)                        153/73 (68/32)
  Etiology                         
    Rheumatic                      201 (90)
    MVP                            17 (7.6)
    HCM                            5 (2.4)
  BNP (pg/mL) at rest              65.24 ± 43.92 (median: 43.5)
  BNP (pg/mL) at exercise (eBNP)   100.24 ± 98.24 (median: 66.5)
    T~1~ (15 - 44)                 76 (34%)
    T~2~ (45 - 104)                77 (34%)
    T~3~ (105 - 400)               70 (31%)

BNP: brain natriuretic peptide; MVP: mitral valve prolapse; HCM: hypertrophic cardiomyopathy.

Clinical and resting echocardiographic data according to tertile of peak eBNP distribution {#s3b}
------------------------------------------------------------------------------------------

The average exercise time was 9.78 ± 3.02 min with no significant difference in peak systolic blood pressure (SBP), increase in SBP, peak heart rate except for a significantly lower exercise time in T~3~. During exercise, 66 (29.5%) stopped exercise due to dyspnea. Of note, patients who had dyspnea had similar resting BNP level (66.13 ± 43.84 pg/mL vs. 64.85 ± 44.58 pg/mL; P = 0.23) but significantly higher eBNP level (136 ± 109.7 pg/mL vs. 84.88 ± 90.2 pg/mL; P \< 0.001) compared with those who did not develop dyspnea. There were no significant differences in indexed LVESV (21.5± 2.4 mL/m^2^, 21.53 ± 2.6 mL/m^2^, 22.69 ± 2.18 mL/m^2^; P = 12), indexed LVEDV (68.7 ± 6.15 mL/m^2^, 67.06 ± 4.77 mL/m^2^, 67.44 ± 5 mL/m^2^; P = 0.5), LVEF (68.17±3.14%, 66.7±2.86%, 67.56±3.16%; P = 0.6) except LVGLS (-23±3%, -20±4%, -17±4%; P \< 0.01) and E/Ea ratio (11.65 ± 1.32, 13.8 ± 1.01, 15.05 ± 2.03; P = 0.001) among T~1~, T~2~ and T~3~, respectively. For MR severity, there were no differences in RV (70.6 ± 4.17 mL, 87.53 ± 11.67 mL, 81.68 ± 10.27 mL; P = 0.5) except ERO (50.47 ± 6.2 mm^2^, 59.94 ± 10.32 mm^2^, 50.06 ± 9.24 mm^2^; P = 0.08), indexed LA volume (36 ± 14 mL/m^2^, 39 ± 14 mL/m^2^, 54 ± 20 mL/m^2^; P \< 0.001) and PASP (33.41 ± 4.32 mm Hg, 39.17 ± 4.38 mm Hg, 44 ± 6.39 mm Hg; P \< 0.02) among T~1~, T~2~ and T~3~, respectively ([Table 3](#T3){ref-type="table"}).

###### Clinical and Echocardiographic Data According to Tertile of Peak eBNP Distribution (N = 223)

  Variables                          T~1~ (\< 15 to 44 pg/mL) (n = 76)   T~2~ (45 - 104 pg/mL) (n = 77)   T~3~ (105 - 400 pg/mL) (n = 70)   P
  ---------------------------------- ----------------------------------- -------------------------------- --------------------------------- ----------
  Age (years)                        29 ± 11                             31 ± 7                           32 ± 8                            0.3
  Male, n (%)                        53 (70)                             53 (69)                          46 (66)                           0.6
  Height (m)                         1.53 ± 0.5                          1.57 ± 0.2                       1.56 ± 0.1                        0.7
  Weight (kg)                        65 ± 12                             63 ± 9.6                         60 .7 ± 14                        0.8
  Treadmill test                                                                                                                            
    Exercise time (min)              11.4 ± 1.73                         11.4 ± 2.2                       6.8 ± 1.6                         \< 0.01
    Peak SBP (mm Hg)                 159 ± 10                            158 ± 12                         150 ± 18                          0.3
    Increase in SBP (mm Hg)          47 ± 10                             37 ± 8                           35 ± 8                            0.6
    Peak HR                          154 ± 8                             151 ± 7                          146 ± 10                          0.2
    Resting BNP (pg/mL)              30.3 ± 8.2                          44.35 ± 17.2                     124.5 ± 17.1                      \< 0.001
  LV geometry and function at rest                                                                                                          
    Indexed LVESV (mL/m^2^)          21.5± 2.4                           21.53 ± 2.6                      22.69 ± 2.18                      0.12
    Indexed LVEDV (mL/m^2^)          68.7 ± 6.15                         67.06 ± 4.77                     67.44 ± 5                         0.5
    LVEF (%)                         68.17 ± 3.14                        66.7 ± 2.86                      67.56 ± 3.16                      0.6
    LVGLS (%)                        -23 ± 3                             \- 20 ± 4                        \- 17 ± 4                         \< 0.01
    E/Ea ratio                       11.65 ± 1.32                        13.8 ± 1.01                      15.05 ± 2.03                      0.001
  MR severity                                                                                                                               
    ERO (mm^2^)                      50.47 ± 6.2                         59.94 ± 10.32                    50.06 ± 9.24                      0.08
    RV (mL)                          70.6 ± 4.17                         87.53 ± 11.67                    81.68 ± 10.27                     0.5
    Indexed LA volume (mL/m^2^)      36 ± 14                             39 ± 14                          54 ± 20                           \< 0.001
    PASP (mm Hg)                     33.41 ± 4.32                        39.17 ± 4.38                     44 ± 6.39                         \< 0.02

SBP: systolic blood pressure; ERO: effective regurgitant orifice; HR: heart rate; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; GLS: global longitudinal strain; PASP: pulmonary artery systolic pressure; RV: regurgitant volume.

Exercise echocardiographic data according to the tertiles of peak eBNP distribution {#s3c}
-----------------------------------------------------------------------------------

There were no significant differences in indexed LVEDV (58 ± 24 mL/m^2^, 59 ± 19 mL/m^2^, 66 ± 22 mL/m^2^; P = 0.52), LVEF (71±9%, 69±10%, 65±13%; P = 0.13) except indexed LVESV (18 ± 7 mL/m^2^, 18 ± 8 mL/m^2^, 26 ± 11 mL/m^2^; P = 0.06), LVGLS (-27±5%, -23±5%, -17±5%; P \< 0.01) and E/Ea ratio (13.52 ± 1.42, 15.17 ± 0.81, 18.87 ± 2.30; P = 0.001) among T~1~, T~2~ and T~3~, respectively. For MR severity, there were significant differences in RV (72 ± 5.9 mL, 82 ± 40 mL, 86 ± 34 mL; P = 0.09), ERO (50.7 ± 10 mm^2^, 55.1 ± 10.3 mm^2^, 61 ± 12.38 mm^2^; P = 0.04), indexed LA volume (42 ± 16 mL/m^2^, 47 ± 18 mL/m^2^, 52 ± 16 mL/m^2^; P \< 0.001) and PASP (59.06 ± 8.4 mm Hg, 64.11 ± 7.4 mm Hg, 74.7 ± 7.8 mm Hg; P \< 0.01) among T~1~, T~2~ and T~3~, respectively ([Table 4](#T4){ref-type="table"}).

###### Exercise Echocardiographic Data According to Tertiles of Peak eBNP Distribution (N = 223)

  Variables                              T~1~ (\< 15 - 44 pg/mL) (n = 77)   T~2~ (45 - 104 pg/mL) (n = 76)   T~3~ (105 - 400 pg/mL) (n = 70)   P value
  -------------------------------------- ---------------------------------- -------------------------------- --------------------------------- ---------
  LV geometry and function at exercise                                                                                                         
    Indexed LVESV (mL/m^2^)              18 ± 7                             18 ± 8                           26 ± 11                           0.06
    Indexed LVEDV (mL/m^2^)              58 ± 24                            59 ± 19                          66 ± 22                           0.52
    LVEF (%)                             71 ± 9                             69 ± 10                          65 ± 13                           0.13
    LVGLS (%)                            -27 ± 5                            -23 ± 5                          -17 ± 5                           \< 0.01
    E/Ea ratio                           13.52 ± 1.42                       15.17 ± 0.81                     18.87 ± 2.30                      0.001
  Exercise MR severity                                                                                                                         
    ERO (mm^2^)                          50.7 ± 10                          55.1 ± 10.3                      61 ± 12.38                        0.04
    RV (mL)                              72 ± 5.9                           82 ± 40                          86 ± 34                           0.09
    Indexed LA volume (mL/m^2^)          42 ± 16                            47 ± 18                          52 ± 16                           0.03
    PASP (mm Hg)                         59.06 ± 8.4                        64.11 ± 7.4                      74.7 ± 7.8                        \< 0.01

ERO: effective regurgitant orifice; HR: heart rate; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; GLS: global longitudinal strain; PASP: pulmonary artery systolic pressure; RV: regurgitant volume.

During follow-up (15 months), pre-defined cardiac events occurred in 83 patients (37.2%): mitral valve replacement (MVR) in 59 (71%) patients (symptomatic: 43 (51%); LV dilatation or dysfunction: 9 (10%); both symptoms and dilatation/dysfunction: 7 (8.4%)). Twenty-four patients (29%) experienced an event other than surgery (CHF hospitalizations: 17 (20%), syncope: 2 (2.5%) related to fast AF, and acute pulmonary edema: 5 (6%)). This was 7.6%, 35% and 69% in T~1~, T~2~ and T~3~, respectively. These patients had a significantly higher eBNP level than without any event (165 ± 119 pg/mL vs. 57 ± 48 pg/mL; P \< 0.001).

Using ROC curve analysis, the best cut-off value of eBNP level to predict cardiac events was 90 pg/mL (sensitivity: 75%; specificity: 88.6%; positive predictive value: 79%; negative predictive value: 83.9%). In addition, by restricting the analysis only to patients with a resting BNP level greater than median, i.e. 43.5 pg/mL, 36 of 60 patients (40%) whose BNP had increased from rest to exercise had a significantly lower event-free survival.

Discussion {#s4}
==========

In normal healthy subjects, BNP significantly increases following standard treadmill exercise which is unrelated to exercise-induced hemoconcentration, gender, age, or body mass index \[[@R08]\]. Similar variations of BNP level after exercise have also reported in various cardiac diseases. In patients with chronic heart failure, exercise levels of BNP appear to be more reliable than their resting level as markers of LV systolic dysfunction and dimensions \[[@R22], [@R23]\] implying that a marked increase in BNP during exercise might occur early in the course of developing chronic heart failure. In addition, eBNP correlates with exercise capacity in such patients.

In our study, patients with asymptomatic MR with normal LV dimensions and function, elevated eBNP was independently associated with subclinical impairment of systolic and diastolic LV function, exercise MR severity, LA dilatation, and reduced cardiac event-free survival. Of note, exercise LV longitudinal function is the main determinant of eBNP, whereas neither resting or exercise LVEF nor the degree of MR at rest was significantly associated with eBNP. Also exercise LVGLS was significantly reduced in T~3~ (-17±5) compared to T~2~ and T~1~ (-27±5 and -23±5), implying EF lacks sensitivity to identify subtle or latent impairment in myocardial systolic function.

Reduced LVGLS has previously been shown to be superior to LVEF to predict persistence of LV systolic dysfunction and worse functional capacity after mitral valve surgery \[[@R24]\]. Consequently, LVGLS which is a rapid, simple, and reproducible echocardiographic parameter, may be integrated into the routine evaluation of patients with MR. Furthermore, the findings of this study reveal that eBNP could be used as a surrogate marker of LV longitudinal dysfunction during exercise regardless of the severity of MR.

eBNP level also correlated well with the estimate of elevated resting LV filling pressures and abnormal exercise LV filling response as significantly higher exercise E/Ea ratio in T~3~ (18.87 ± 2.30) compared to T~1~ and T~2~ (13.52 ± 1.42 and 15.17 ± 0.81). Previous studies by Mak et al \[[@R25]\] also reported that the combined consideration of BNP and the E/Ea ratio is helpful in the assessment of LV diastolic function. The higher LA volume index obtained in T~3~ compared to T~1~ and T~2~ (42 ± 16 and 47 ± 18) may be related to the concomitant impact of elevated LV filling pressures. Similar findings were concluded from studies by Le Tourneau et al \[[@R26]\] and Rusinaru et al \[[@R27]\] that LA enlargement is a good marker of advanced stage of primary MR. In light of these results, exercise BNP appears to be a valuable surrogate marker of LV diastolic and systolic dysfunctions and of their potential worsening during exercise.

The management of asymptomatic patients with preserved LV function remains controversial as revealed in "watchful waiting" strategy proposed by Rosenhek et al \[[@R28]\] and "early surgery" proposed by Montant et al \[[@R29]\]. It underlines the importance to refine the identification of high-risk patients as those with low risk could be safely managed conservatively with regular follow-up, whereas those identified at higher risk could be referred for early surgery. Nevertheless, such management necessitates the identification of trustworthy markers able to discriminate patients at low vs. high risk of developing symptoms under conservative management. Parameters and criteria recommended in the guidelines (LV dilatation/dysfunction, AF, and PAH) are generally associated with reduced postoperative survival. The measurement of resting BNP may aid the clinical decision making for asymptomatic MR patients as shown by Sutton et al \[[@R30]\], Detaint et al \[[@R17]\], and Pizarro et al \[[@R31]\]. Magne et al \[[@R21]\] showed that eBNP may improve risk stratification beyond obtained from demographics, echocardiographic data, and resting BNP, and may thus be helpful to unmask patients at high risk of developing rapid cardiac events. In their study of 113 asymptomatic patients with moderate to severe degenerative MR and preserved LV function, comprehensive resting and exercise echocardiography was performed where BNP level significantly increased from rest to exercise (P \< 0.0001). The independent determinants of eBNP were resting E/Ea ratio (P = 0.043), indexed LA volume (P = 0.022), and exercise LVGLS (P = 0.001) with a significant graded relationship between increasing BNP level at exercise and increased incidence of cardiac events (death, CHF, need for MVR driven by symptoms, or LV dilatation/dysfunction onset) at 1 year (11+5% vs. 14+6% vs. 43.5+9%) and 2 years (21+7% vs. 40+8% vs. 67+9%) in three tertiles. On multivariable analysis, after adjustment for demographic, echocardiographic data and resting BNP level, eBNP remained significantly associated with increased risk of cardiac events during the follow-up (hazard ratio 2.8 and 3.4 for T~2~ and T~3~ as compared with T~1~). The best cut-off value of eBNP level to predict cardiac events was 64 pg/mL (sensitivity: 87%; specificity: 61%). The present study also showed comparable results with best cut-off value of eBNP 90 pg/mL with similar accuracy for event prediction. Measurement of BNP at exercise is straightforward and can easily be included in the context of standard exercise testing or exercise stress echocardiography. The biphasic behavior of myocardial strain may also account in part for conflicting reports on the value of preoperative speckle-tracking strain imaging in predicting postoperative LV dysfunction \[[@R14]\]. Although it requires further larger studies using mortality as an endpoint, our study suggests that patients with a high eBNP level might potentially benefit from early referral to surgery. It has also shown that elevated eBNP level may have an additive prognostic importance over resting BNP level.

Study limitations {#s4a}
-----------------

Small sample size of the study and a cut-off value of 90 pg/mL were data driven and need to be validated in larger studies. Also the use of overall mortality as an endpoint to test the prognostic implication of eBNP could probably be more robust.

Conclusions {#s4b}
-----------

In asymptomatic patients with primary MR, eBNP level provides incremental prognostic value beyond what is achieved by demographic, echocardiographic data and resting BNP level. Those with elevated eBNP may be considered for early mitral valve surgery as they are at higher risk of reduced cardiac event-free survival, thus supporting the notion for the systematic measurement of BNP at the time of exercise testing or exercise stress echocardiography.
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